Recently, several teams including ourselves have reported encouraging results on CYP4V2 gene replacement therapy in BCD-iPSC-RPE cells and Cyp4v3 KO mice18–20. This evidence concerns the gene CYP4V2 and Bietti crystalline corneoretinal dystrophy.